New Delhi: The Central Drugs Standard Control Organisation (DCGI) has issued a warning to pharmaceutical companies against indirect advertising of prescription-only medicines used for obesity and related conditions.
According to the regulator, some firms have been promoting drugs meant to be taken only on a doctor’s advice—such as medicines for obesity, high fat levels and metabolic issues—under the guise of public awareness campaigns. Complaints on such promotions were received by the DCGI.
In a statement, DCGI Director Dr Rajeev Singh Raghuvanshi said manufacturers, importers and authorised marketing companies must strictly follow the Drugs and Cosmetics Act and its rules. He reiterated that advertising prescription-only medicines through print, electronic media, the internet or social media is prohibited.
The regulator added that even indirect promotions aimed at keeping a drug’s name in public memory would be treated as violations. Companies were also asked to submit a detailed risk management plan to monitor and prevent misuse.
The DCGI noted that obesity requires comprehensive treatment including diet control and exercise, and cautioned against advertisements that create a misleading impression that medicines alone can provide a complete solution.
